Starting on:
May 13, 2021
Ending on:
May 13, 2021
Moderator(s):
Venue:
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
May 13, 2021
Ending on:
May 13, 2021
Moderator(s):
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
JOURNAL CLUB - 13/05/2021
Starting on:
May 13, 2021 8:00 AM
May 13, 2021 8:00 AM
Ending on:
May 13, 2021 9:00 AM
May 13, 2021 9:00 AM
Venue:
THE KAREN HOSPITAL
THE KAREN HOSPITAL
Description
GALACTIC-HF: Omecamtiv mecarbil in patients with heart failure with reduced ejection fraction
Objectives
- The goal of the trial was to evaluate the selective cardiac myosin activator omecamtiv mecarbil compared with placebo among patients with heart failure with reduced ejection fraction (HFrEF).
- The primary outcome, cardiovascular death or HF event at a median of 21.8 months, occurred in 37.0% of the omecamtiv mecarbil group compared with 39.1% of the placebo group (p = 0.03).
- In patients with symptomatic HF with reduced ejection fraction (HFrEF), omecamtiv mecarbil did not reduce the risk of death, HF hospitalizations vs placebo over a median of 22 months.
- Omecamtiv mecarbil did reduce the primary composite outcome (CV death, HF hospitalization or worsening HF requiring urgent outpatient visit); however, this was driven by urgent outpatient visits & is of unclear clinical importance.
Presenters
-
Dr.
JASON MUGA
MEDICAL OFFICER
The Karen Hospital -
Dr.
GEORGE OTIENO
MEDICAL OFFICER
The Karen Hospital